2013•GeneRequires access

Reduced glucosylceramide in the mouse model of Fabry disease: Correction by successful enzyme replacement therapy

Rui Quinta, Daniel Nava Rodrigues, Marisa Sofia de Oliveira Assunção, M. Fátima Macedo, Olga Azevedo, Damião Cunha, Pedro Oliveira, Maria Clara Sá Miranda

Open publisher page 9 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Globotriaosylceramide, Fabry disease, Enzyme replacement therapy, Sphingolipid, Biology, Knockout mouse, Alpha-galactosidase, Ceramide

Back to paper search Browse research topics Original source

Reduced glucosylceramide in the mouse model of Fabry disease: Correction by successful enzyme replacement therapy — Research Paper | ScholarLens